IFN alpha-7, IFN-alpha-7, IFN alpha-J, LeIF J, IFN alpha-J1, IFN-alpha-J1, IFNA7, IFNA-J, IFN-alphaJ.
IFN alpha-7, IFN-alpha-7, IFN alpha-J, LeIF J, IFN alpha-J1, IFN-alpha-J1, IFNA7, IFNA-J, IFN-alphaJ.
IFN-α7 is one of the 13 subtypes of interferon-alpha, which are produced mainly by leukocytes . The recombinant form of IFN-α7 is produced using mammalian cell expression systems, such as Chinese hamster ovary (CHO) cells . This method ensures that the recombinant protein is similar to the naturally occurring human protein in terms of structure and function.
The molecular mass of recombinant human IFN-α7 is approximately 22 kDa . It is typically formulated in a phosphate buffer solution containing human serum albumin (HSA) and saccharose to maintain stability and solubility .
IFN-α7 exerts its effects by binding to a specific cell surface receptor complex known as IFNAR, which consists of two subunits: IFNAR1 and IFNAR2 . Upon binding to this receptor, a signaling cascade is initiated, involving the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways . This leads to the formation of the ISGF3 transcriptional complex, which binds to interferon-stimulated response elements (ISRE) in the promoters of numerous interferon-stimulated genes (ISGs) .
The activation of these genes results in a wide range of biological activities, including:
Recombinant human IFN-α7 is primarily used in research settings to study its biological activities and potential therapeutic applications . It has shown promise in the treatment of viral infections, certain types of cancer, and immune-related disorders . However, its clinical use is limited by its short half-life, which necessitates frequent dosing .